DTB podcast-logo

DTB podcast

Health & Wellness Podcasts >

More Information

Location:

United Kingdom

Twitter:

@DTB_BMJ

Language:

English


Episodes

Here's your New DTB!

9/12/2018
More
In September's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the changes to DTB that have taken place this month and discuss the background and rationale to these changes. Read this month's editorial: https://dtb.bmj.com/content/56/9/98. The editors also consider the place for monitored dosage systems (https://dtb.bmj.com/content/56/9/102) and discuss the evidence for using labetalol as a first-line treatment option for hypertension in...

Duration:00:08:55

August 2018: what’s your position on giving birth?

8/6/2018
More
In the August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the results of an awarding research paper that assessed the impact of spending the second stage of labour either in a recumbent or upright position. Read the editorial: https://dtb.bmj.com/content/56/8/85. The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines...

Duration:00:11:13

July 2018: managing herbal-drug interactions

7/11/2018
More
In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines. Read the editorial: https://dtb.bmj.com/content/56/7/73. The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).

Duration:00:13:06

June 2018: Antidepressants - there is no news

7/2/2018
More
In the June’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether a recently published large meta-analysis on the effectiveness of antidepressants tells us anything new. Read the editorial here: dtb.bmj.com/content/56/6/61. The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).

Duration:00:10:52

May 2018: Does pulmonary rehabilitation need more PR?

5/9/2018
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49. The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence...

Duration:00:11:59

April 2018: STOMP - time to make more noise

4/11/2018
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national campaign in England that is tackling the inappropriate use of antipsychotic and antidepressant medicines in people with learning or intellectual disability. Read the article: http://dtb.bmj.com/content/56/4/37. The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD...

Duration:00:15:32

March 2018: Do hypertension guidelines put the person first?

3/12/2018
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the difficulties in implementing clinical guidelines for the management of elevated blood pressure and the potential impact of changes in the threshold for a diagnosis of hypertension (http://dtb.bmj.com/content/56/3/25). The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30)...

Duration:00:11:15

February 2018: Clinical guidelines - more PDAs please

2/9/2018
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of developing patient decision aids to support the implementation of clinical guidelines (http://dtb.bmj.com/content/56/2/13). The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception...

Duration:00:13:10

January 2018: No alchemy for obesity

1/2/2018
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of exercise, diet and behaviour modification in the management of obesity and consider the limitations of anti-obesity drugs. http://dtb.bmj.com/content/56/1/1 The editors also review the evidence for ▼patiromer, a cation exchange polymer, that has recently been marketed for the management of hyperkalaemia - http://dtb.bmj.com/content/56/1/6 and discuss the management...

Duration:00:12:35

December 2017: Shared care protocols – have they had their day?

12/4/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenge of prescribing specialist drugs in primary care and highlight problems associated with the use of shared care protocols. http://dtb.bmj.com/content/55/12/133 The editors also review the evidence for an inhaler containing beclometasone, formoterol and glycopyrronium that has recently been licensed for the management of COPD - http://dtb.bmj.com/content/55/12/138 - and...

Duration:00:12:32

November 2017: Prescribing in pregnancy - stop stopping and start planning

11/6/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenges associated with prescribing for long-term conditions in women who are pregnant and raise concerns that medicines may be stopped inappropriately. Read the editorial here: http://dtb.bmj.com/content/55/11/121. The editors also review a combination product containing naltrexone and bupropion that is licensed for the management of obesity -...

Duration:00:14:27

October 2017: Flagging risk

10/9/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the fragmented approach to communicating additional risk minimisation measures for medicines. Article available here: http://dtb.bmj.com/content/55/10/1. The editors also review the long-term safety of PPIs (http://dtb.bmj.com/content/55/10/117) and discuss the use of the live attenuated influenza vaccine for children (http://dtb.bmj.com/content/55/10/114).

Duration:00:12:10

September 2017: Vitamin D and adolescents: a forgotten ‘at risk’ group?

9/4/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss vitamin D deficiency in teenagers and highlight the challenge of implementing national recommendations on vitamin D intake in young people. Full article here: http://dtb.bmj.com/content/55/9/1. The editors also review the management of scarlet fever (http://dtb.bmj.com/content/55/9/102.2) and consider two drugs (baricitinib and tofacitinib) recently licensed for the management of...

Duration:00:11:18

August 2017: What price drugs online?

7/26/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the supply of medicines from online primary care services (article here: http://dtb.bmj.com/content/55/8/85). The editors also review two recently licensed drugs: eluxadoline, a mixed opioid receptor agonist/antagonist for irritable bowel syndrome (http://dtb.bmj.com/content/55/8/90) and an oral formulation of glycopyrronium (http://dtb.bmj.com/content/55/8/93) for severe drooling in...

Duration:00:12:00

July 2017: The good, the bad and the ugly

7/5/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the role of Electroconvulsive Therapy (ECT) in the management of psychiatric disorders. Article here: http://dtb.bmj.com/content/55/7/1. The editors also discuss the use of liraglutide for obesity (related article here: http://dtb.bmj.com/content/55/7/78)and highlight some of the challenges associated with the management of people with clinical features of both asthma and COPD...

Duration:00:13:36

June 2017: Turning the tide of high-dose inhaled corticosteroids

6/5/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of high-dose inhaled corticosteroids in asthma and COPD. The editors also highlight some of the challenges associated with the management of superficial venous thrombosis of the leg and discuss the use of carbohydrate deficient transferrin as a biomarker for the assessment of chronic alcohol use. Read more about the DTB's June 2017 issue:...

Duration:00:11:16

May 2017: Rational rationing in the NHS?

5/3/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss attempts by the NHS in England to target £400m of prescribing expenditure that is reported to be wasted on a range of products that are considered to be of low value. Editorial available here: http://dtb.bmj.com/content/55/5/49 The editors also review the evidence for the use of off-label testosterone supplementation in menopausal women (http://dtb.bmj.com/content/55/5/57) and discuss...

Duration:00:13:02

April 2017: Prevention of type 2 diabetes - where do you draw the line?

3/28/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national initiative to identify and manage people at high risk of developing type 2 diabetes. Full article available here: http://dtb.bmj.com/content/55/4/37. The editors also review the evidence for an HRT product containing bazedoxifene and conjugated oestrogens (http://dtb.bmj.com/content/55/4/42) and discuss a new formulation of lidocaine and prilocaine licensed for treatment of...

Duration:00:13:47

March 2017: Better PrEParation needed?

3/14/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the implications related to funding of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV). They consider the Court of Appeal decision on funding and the role of clinical and health economic evaluations for preventative treatments. Full article available here: http://dtb.bmj.com/content/55/3/25. The editors also review the evidence for a new formulation of...

Duration:00:12:57

February 2017: Spironolactone - potion or poison?

2/6/2017
More
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of hyperkalaemia associated with spironolactone in people with heart failure. They consider recent advice issued by the Medicines and Healthcare products Regulatory Agency and highlight the importance of regular monitoring of potassium and renal function. The editors also review the evidence for daclizumab, a drug for relapsing multiple sclerosis, and provide a brief...

Duration:00:14:31